Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedOct 03, 2025
DataAggregated Company Financials
Companies548
- 7D5.7%
- 3M10.1%
- 1Y0.1%
- YTD11.5%
In the last week, the Biotech industry is up 5.7%, with AbbVie up 8.2%. During this same period, the MoonLake Immunotherapeutics underperformed, falling 87%. The industry has been flat over the past 12 months despite the gain this week. Earnings are forecast to grow by 25% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 03 Oct 2025 | US$1.1t | US$163.5b | -US$18,231,777,884.78 | 16.6x | -61.3x | 6.8x |
| Sun, 31 Aug 2025 | US$1.1t | US$163.5b | -US$18,374,916,758.56 | 15.4x | -57.4x | 6.5x |
| Tue, 29 Jul 2025 | US$992.7b | US$155.1b | -US$22,907,102,966.39 | 14.7x | -43.3x | 6.4x |
| Thu, 26 Jun 2025 | US$932.5b | US$156.0b | -US$23,833,808,017.77 | 16.8x | -39.1x | 6x |
| Sat, 24 May 2025 | US$908.4b | US$155.9b | -US$24,112,206,612.11 | 15.6x | -37.7x | 5.8x |
| Mon, 21 Apr 2025 | US$756.9b | US$119.2b | -US$36,619,881,205.07 | 19.4x | -20.7x | 6.3x |
| Wed, 19 Mar 2025 | US$848.7b | US$118.4b | -US$37,468,766,996.50 | 19.6x | -22.6x | 7.2x |
| Fri, 14 Feb 2025 | US$828.4b | US$118.3b | -US$35,648,753,290.57 | 17.4x | -23.2x | 7x |
| Sun, 12 Jan 2025 | US$947.8b | US$149.4b | -US$26,263,014,335.71 | 16.6x | -36.1x | 6.3x |
| Tue, 10 Dec 2024 | US$1.0t | US$150.0b | -US$26,481,719,164.07 | 17.7x | -39.1x | 6.9x |
| Thu, 07 Nov 2024 | US$1.1t | US$148.4b | -US$30,716,238,423.67 | 17.2x | -35.3x | 7.3x |
| Sat, 05 Oct 2024 | US$879.9b | US$113.1b | -US$35,952,253,973.77 | 22x | -24.5x | 7.8x |
| Mon, 02 Sep 2024 | US$909.4b | US$113.1b | -US$35,712,101,098.38 | 24x | -25.5x | 8x |
| Wed, 31 Jul 2024 | US$1.2t | US$164.9b | -US$28,962,809,067.11 | 26.4x | -42.6x | 7.5x |
| Fri, 28 Jun 2024 | US$1.1t | US$164.4b | -US$27,987,328,341.41 | 27.9x | -41x | 7x |
| Sun, 26 May 2024 | US$1.1t | US$164.6b | -US$26,653,350,594.72 | 23.8x | -42.2x | 6.8x |
| Tue, 23 Apr 2024 | US$1.1t | US$164.2b | -US$23,311,155,066.52 | 20.4x | -45.9x | 6.5x |
| Thu, 21 Mar 2024 | US$1.2t | US$164.4b | -US$23,861,120,065.01 | 21.1x | -48.9x | 7.1x |
| Sat, 17 Feb 2024 | US$1.2t | US$169.1b | -US$20,461,379,458.58 | 15.7x | -57.1x | 6.9x |
| Mon, 15 Jan 2024 | US$1.4t | US$204.8b | -US$22,497,556,941.00 | 18.8x | -63.9x | 7x |
| Wed, 13 Dec 2023 | US$1.3t | US$204.6b | -US$22,084,753,624.00 | 19x | -59.4x | 6.4x |
| Fri, 10 Nov 2023 | US$1.2t | US$204.3b | -US$22,786,529,302.00 | 18.9x | -54.1x | 6x |
| Sun, 08 Oct 2023 | US$1.3t | US$207.4b | -US$13,060,168,797.00 | 17.2x | -96.3x | 6.1x |
| Tue, 05 Sep 2023 | US$1.3t | US$207.5b | -US$12,454,516,459.00 | 18.4x | -103.9x | 6.2x |
| Thu, 03 Aug 2023 | US$1.1t | US$187.2b | -US$14,216,380,818.00 | 13.7x | -79.9x | 6.1x |
| Sat, 01 Jul 2023 | US$1.1t | US$186.2b | -US$16,042,400,813.00 | 13.7x | -70x | 6x |
| Mon, 29 May 2023 | US$1.1t | US$185.9b | -US$16,045,777,796.00 | 11.2x | -69.9x | 6x |
| Wed, 26 Apr 2023 | US$1.2t | US$198.4b | -US$3,227,872,728.00 | 13.1x | -364.9x | 5.9x |
| Fri, 24 Mar 2023 | US$1.1t | US$199.5b | -US$3,534,604,837.00 | 12.6x | -316.2x | 5.6x |
| Sun, 19 Feb 2023 | US$1.2t | US$202.6b | -US$64,851,937.00 | 16.5x | -17785.7x | 5.7x |
| Tue, 17 Jan 2023 | US$1.2t | US$203.7b | US$1.8b | 14.5x | 670.9x | 5.8x |
| Thu, 15 Dec 2022 | US$1.2t | US$203.0b | US$1.5b | 14.7x | 771.2x | 5.8x |
| Sat, 12 Nov 2022 | US$1.1t | US$201.0b | US$2.5b | 14.6x | 444x | 5.5x |
| Mon, 10 Oct 2022 | US$1.0t | US$206.1b | US$5.4b | 14.9x | 190.4x | 5x |
Price to Earnings Ratio
190.4x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.5x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 7.4% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 1.62% | |
| Healthcare | 6.37% | |
| Biotech | 5.66% | |
| Biotech | 5.66% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ABBV AbbVie | US$236.56 | 8.2% +US$31.8b | 21.0% | PE112.2x | |
| AMGN Amgen | US$297.40 | 9.7% +US$14.1b | -6.3% | PE24.2x | |
| VRTX Vertex Pharmaceuticals | US$408.85 | 7.1% +US$6.9b | -9.9% | PE28.8x | |
| REGN Regeneron Pharmaceuticals | US$600.00 | 8.0% +US$4.6b | -40.9% | PE14x | |
| INSM Insmed | US$152.80 | 12.7% +US$3.6b | 114.0% | PS81.1x |